promised skin results in antigen specific immunosuppression. Australia 7001 LC depletion has therefore been proposed as a key event Epidermal Langerhans cells (LC) are an integral componassociated with the pathogenesis of skin cancer as it will allow ent of the skin immune system as they initiate immune aberrant cells to escape immune detection (2, 6, 7, 9) . responses to a variety of antigens, including tumor antigens.
LC depletion has therefore been proposed as a key event Epidermal Langerhans cells (LC) are an integral componassociated with the pathogenesis of skin cancer as it will allow ent of the skin immune system as they initiate immune aberrant cells to escape immune detection (2, 6, 7, 9) . responses to a variety of antigens, including tumor antigens.
The ability of carcinogens to cause LC depletion is partly When skin is exposed to carcinogenic doses of ultravioletdue to the carcinogens being treated as antigens. This in turn B irradiation, chemical carcinogens or tumor promoters triggers LC migration to the local lymph node to induce an there is a significant reduction of LC density. This causes immune response (10) and leaves the epidermis depleted of the skin to be immunocompromised and provides an oppor-LC and immunologically compromised. Contact sensitizing tunity for aberrant cells to escape immune detection and antigens have also been shown to induce LC depletion from develop into tumors. Consequently LC depletion is a key murine skin (8) . We have recently demonstrated that such event associated with the pathogenesis of skin cancer. We antigens induce LC depletion in a dose-dependent manner. Skin propose that LC depletion contributes to tumor promotion exposed to a high concentration of antigen is immunologically and therefore any agents that reduce LC number, e.g.
compromised as any new antigen applied through this skin the contact sensitizing antigen 2,4,6-trinitrochlorobenzene generates active immunosuppression rather than a protective (TNCB), may also contribute to tumor promotion. This immune response (11) . These findings indicate that antigens proposal was evaluated in cutaneous carcinogenesis by have the ability to modulate the skin immune system in such treating mouse skin with a tumor initiating dose of the a way that the treated skin becomes immunocompromised carcinogen 7,12-dimethylbenz[a]anthracene (DMBA) folsimilar to that caused by chemical and physical carcinogens. lowed by a tumor promoter. The initiating dose of DMBA Carcinogenesis, including cutaneous carcinogenesis, can be did not cause LC depletion or tumor development. However, classified into initiation and promotional phases (12, 13) . The if the DMBA-treated skin was then exposed to a concentrainitial stage, tumor initiation, will occur following exposure tion of TNCB that caused LC depletion, skin tumors to a tumor initiator such as urethane and results in phenodeveloped. This is analogous to the classical initiator/ typically silent alterations including somatic mutations and promoter system with an LC-depleting dose of TNCB epigenetic events (12, 14, 15) . However, the local antigen precontributing to tumor promotion. Further, this promotion senting cells, i.e. the LC, are unaffected and their density effect was independent of the commencement time of the remains unaltered (7) . No detectable tumors develop at this promoter application, as 2% TNCB applied either 1 or 12 stage. The latter stage, tumor promotion, will occur following weeks after DMBA initiation induced tumor development.
repeated exposures to tumor promoters such as TPA, involves Analysis of the association of LC depletion with immunomany different cellular effects including the ability to promote suppression and tumor promotion, showed that these events skin inflammation and hyperplasia (16) and activate protein were linked, irrespective of the agent that caused the depletion. It is therefore concluded that LC depletion and kinase C leading to protein phosphorylation and proliferation local immunosuppression are important aspects of tumor (17) . Tumor promoters also deplete LC from the epidermis (7). promotion in cutaneous carcinogenesis and non-carcino-
The fact that carcinogens and tumor promoters may behave genic agents may have tumor promoter activities.
as antigens and induce an immune response (10) combined with the observation that antigens may cause LC depletion (8, 11) , similar to carcinogens and tumor promoters, indicates that these agents share a number of properties. As both tumor promoters and antigens can induce LC depletion, then antigens Langerhans cells (LC*) are a major component of the skin may also have tumor promoting capacities. The present study immune system. They are antigen presenting cells that recoginvestigated this proposal by evaluating the importance of LC nize and transport antigen to the local lymph node where it is depletion in tumor development, as part of the tumor promotion presented in a processed form to antigen specific T-lymphocytes process. Tumor initiation/promotion experiments were under-(1-3). It is essential that the skin has an adequate density of taken using the shaved dorsal trunk skin of female BALB/c LC, otherwise an immune response is not generated (4, 5) .
mice treated with either the complete chemical carcinogen Exposure of mouse skin to the complete chemical carcinogen DMBA, the tumor promoter TPA (both from Sigma) or the 7,12-dimethylbenz[a]anthracene (DMBA) (6), the tumor proantigen TNCB (from Tokyo-Kasei) in appropriate combinations moter 12-O-tetradecanoylphorbol-13-acetate (TPA) (7) or and concentrations. The density of LC in the epidermis was ultraviolet-B (UVB) irradiation (4,8) causes significant LC determined by preparing epidermal sheets using a modified EDTA separation procedure, and LC were identified with an 100 µl of 0.1% DMBA (s), two applications of 100 µl of 0.1% DMBA at 7 days apart (j), one application of 100 µl of 1% DMBA (n) or one application of 100 µl of 0.1% DMBA followed by 100 µl of 0.005% TPA twice a week for 10 consecutive weeks (r). Tumors were enumerated weekly after the DMBA application and the average number of tumors per mouse calculated. (B) Dorsal trunk skin was treated with 100 µl of 0.1% DMBA followed either 1 week later (j) or 12 weeks later (r) with multiple applications of 100 µl of 2% TNCB, which was applied through the DMBA treated site once a week for the next 4 consecutive weeks (↓ represents the first application of TNCB). Tumors were counted weekly after DMBA application and the average number of tumors per mouse calculated. Results represent the mean number of tumors from six mice in each group.
and the immune response reverts to normal. This provides additional support for the proposal that immune suppression 0.1% DMBA, multiple applications of 100 µl of 2% TNCB induced tumor development ( Figure 3B ), whereas 20 weeks described (18) . Tumor development (usually papillomas but occasionally squamous cell carcinomas) were scored at weekly after the mice were treated with only a single dose of 0.1% DMBA, there was no LC depletion and no tumor development. intervals and the average number of tumors per mouse (from a group of six mice) was determined. The mice were observed This demonstrates that an LC depleting dose of TNCB has tumor promoter activity and that LC depletion, even if caused for a maximum of 20 weeks following the first treatment. Mice were killed earlier if they showed signs of discomfort.
by antigens, can account for this aspect of promotion. The tumor promotion effect of LC-depleting doses of TNCB There was a direct correlation between LC depletion and tumor promotion. This was first highlighted by the observation was independent of the commencement time, as applications of 2% TNCB either 1 week or 12 weeks after DMBA initiation, that LC depletion induced by DMBA or TNCB was dosedependent ( Figure 1A and B) . When analyzing DMBA it was caused tumor development ( Figure 3B ). Consequently, once a cell has undergone initiation by 0.1% DMBA, the effect is found that a single high dose (100 µl of 1%) caused LC depletion from the epidermis but not a single low dose long term and LC depletion is sufficient to help drive the process through the promotion phase. During the latency period (100 µl of 0.1%). Further investigations revealed that two applications of this low dose of DMBA were required to cause between the initial DMBA treatment and TNCB application it is tempting to speculate that the LC are actively involved in LC depletion ( Figure 2 ). As shown in Figure 3A , the doses of DMBA which caused LC depletion (i.e. 100 µl of 1% or two protection against tumor development. Although the evidence indicates that DMBA-and TPA-induced LC depletion is a key applications of 100 µl of 0.1%) also induced tumor formation, thus providing support for the correlation between LC depletion component of the tumor promotion process (6, 19) it could be argued that as both of these agents are carcinogens, their and tumor development.
This association was further extended to the tumor promoter involvement in tumor growth was merely through their carcinogenic activity, and that LC depletion was coincidental. Our TPA, which required multiple applications following DMBA initiation to cause tumor development ( Figure 3A) . It should initial studies with DMBA showed that LC repopulation of the depleted epidermis coincided with tumor regression (6) be noted that multiple applications of TPA were also necessary to cause LC depletion (Figure 2) . The requirement for multiple suggesting an active role for LC in tumor immunity. More direct evidence that LC present tumor antigens was provided applications of TPA to promote tumor formation is a characteristic of tumor promoters. Further, as tumor promotion is by Grabbe and colleagues who demonstrated that LC could present fibrosarcoma cells to induce a protective immune reversible, the effects of tumor promoters can be overcome. genes involved in the cell cycle (14) . Our studies indicate that 20. Grabbe,S., Bruvers,S., Gallo,R.L., Knisely,T.L., Nazareno,R. and LC depletion, which leads to immunosuppression, is also a induce LC depletion may have a role in tumor promotion February 11, 1997 by establishing an immunosuppressive environment. Once a reduction in anti-tumor immunity occurs through a reduction in the number of available LC, the pre-malignant cells may obtain a proliferative advantage and develop unhindered.
